

Maria Laura Stromillo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12016702/publications.pdf>

Version: 2024-02-01

32
papers

1,928
citations

394421
19
h-index

414414
32
g-index

34
all docs

34
docs citations

34
times ranked

2854
citing authors

#	ARTICLE	IF	CITATIONS
1	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 780-789.	5.3	370
2	Association of Neocortical Volume Changes With Cognitive Deterioration in Relapsing-Remitting Multiple Sclerosis. <i>Archives of Neurology</i> , 2007, 64, 1157.	4.5	203
3	Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. <i>EBioMedicine</i> , 2021, 72, 103581.	6.1	184
4	Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309903.	1.9	162
5	Cognitive reserve and cortical atrophy in multiple sclerosis. <i>Neurology</i> , 2013, 80, 1728-1733.	1.1	113
6	Structural <scp>MRI</scp> correlates of cognitive impairment in patients with multiple sclerosis. <i>Human Brain Mapping</i> , 2016, 37, 1627-1644.	3.6	99
7	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	3.7	86
8	Longitudinal Assessment of Multiple Sclerosis with the Brain-AGE Paradigm. <i>Annals of Neurology</i> , 2020, 88, 93-105.	5.3	79
9	Relevance of Brain Lesion Location to Cognition in Relapsing Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e44826.	2.5	78
10	Improving the Characterization of Radiologically Isolated Syndrome Suggestive of Multiple Sclerosis. <i>PLoS ONE</i> , 2011, 6, e19452.	2.5	74
11	Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. <i>Neurology</i> , 2013, 80, 2090-2094.	1.1	63
12	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. <i>EBioMedicine</i> , 2022, 80, 104042.	6.1	54
13	Appraisal of Brain Connectivity in Radiologically Isolated Syndrome by Modeling Imaging Measures. <i>Journal of Neuroscience</i> , 2015, 35, 550-558.	3.6	42
14	Systemic Blood Pressure Profile in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. <i>Stroke</i> , 2005, 36, 2554-2558.	2.0	37
15	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1034-1040.	3.0	37
16	Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2106-2111.	3.0	30
17	Long-term assessment of no evidence of disease activity in relapsing-remitting MS. <i>Neurology</i> , 2015, 85, 1722-1723.	1.1	26
18	Mitochondrial dysfunction in hereditary spastic paraparesis with mutations in DDHD1/SPG28. <i>Journal of the Neurological Sciences</i> , 2016, 362, 287-291.	0.6	24

#	ARTICLE	IF	CITATIONS
19	Gray matter atrophy cannot be fully explained by white matter damage in patients with MS. Multiple Sclerosis Journal, 2021, 27, 39-51.	3.0	21
20	Structural and metabolic damage in brains of patients with SPG11-related spastic paraplegia as detected by quantitative MRI. Journal of Neurology, 2011, 258, 2240-2247.	3.6	19
21	Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability. Frontiers in Neurology, 2017, 8, 608.	2.4	19
22	Impaired vasoreactivity in mildly disabled CADASIL patients. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 268-274.	1.9	18
23	Effects of Sapropterin on Endothelium-Dependent Vasodilation in Patients With CADASIL. Stroke, 2014, 45, 2959-2966.	2.0	16
24	Dynamics of pseudoatrophy in RRMS reveals predominant gray matter compartmentalization. Annals of Clinical and Translational Neurology, 2021, 8, 623-630.	3.7	14
25	Effect of BDNF Val66Met polymorphism on hippocampal subfields in multiple sclerosis patients. Molecular Psychiatry, 2022, 27, 1010-1019.	7.9	10
26	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. European Journal of Neurology, 2022, 29, 535-542.	3.3	8
27	Brain metabolism changes after therapy with chenodeoxycholic acid in a case of cerebrotendinous xanthomatosis. Neurological Sciences, 2013, 34, 1693-1696.	1.9	6
28	The dilemma of benign multiple sclerosis: Can we predict the risk of losing the "benign status"? A 12-year follow-up study. Multiple Sclerosis and Related Disorders, 2018, 26, 71-73.	2.0	6
29	Mapping the Progressive Treatment-Related Reduction of Active MRI Lesions in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 585296.	2.4	4
30	First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study. Multiple Sclerosis and Related Disorders, 2020, 42, 102059.	2.0	4
31	Vitamin D levels in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Neurological Sciences, 2017, 38, 1333-1336.	1.9	3
32	Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course. Multiple Sclerosis Journal, 2022, 28, 154-159.	3.0	3